ATNX News and Press, Athenex Inc. From 11/08/22

BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate ...

Athenex, Inc. (ATNX) Q3 2022 Earnings Conference Call November 03, 2022 08:00 AM ET Company Participants Tim McCarthy - MD, Investor Relations Johnson Lau - Chief Executive Officer Dan Lang - President, Athenex Cell Therapy Darrel Cohen - Chief Medical Office...

Athenex ( NASDAQ: ATNX ) shares gained over 4% Thursday morning after the biopharmaceutical company's request was granted for continued listing on The Nasdaq Stock Market. A Nasdaq Hearings Panel has granted the company's request for continued listing, subject to its s...

Athenex press release ( NASDAQ: ATNX ): Q3 GAAP EPS of -$0.14 beats by $0.01 . Revenue of $31.3M (+19.0% Y/Y) beats by $2.38M . As of September 30, 2022, the Company had cash and cash equivalents, restricted cash, and short-term investments of $41.4M. The C...

BUFFALO, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that a Nasdaq Hearings...

Bolstered balance sheet with $30 million public offering of common stock and warrants Nasdaq Hearing Panel grants Athenex’s request for continued listing Athenex is in the final stages of closing the sale of the China API operations I-SPY 2 study with Oral...

Athenex ( NASDAQ: ATNX ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is -$0.14 and the consensus Revenue Estimate is $28.92M (-10.5% Y/Y). Over the last 1 year, ATNX has beaten EPS estimates ...

BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a c...

Special Stockholder Meeting will be held as a virtual meeting on November 22, 2022 at 9:30 a.m. Eastern Time BUFFALO, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercial...

BUFFALO, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present...